JP2025502602A - ピリミジン複素環式化合物、その調製方法及び医薬用途 - Google Patents

ピリミジン複素環式化合物、その調製方法及び医薬用途 Download PDF

Info

Publication number
JP2025502602A
JP2025502602A JP2024529739A JP2024529739A JP2025502602A JP 2025502602 A JP2025502602 A JP 2025502602A JP 2024529739 A JP2024529739 A JP 2024529739A JP 2024529739 A JP2024529739 A JP 2024529739A JP 2025502602 A JP2025502602 A JP 2025502602A
Authority
JP
Japan
Prior art keywords
group
alkylene
ring
compound
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502602A5 (enExample
Inventor
ルー，ホンフー
ペン，ジンジン
ディン，シャオ
リウ，ジンシン
リウ，インタオ
レン，フェン
ジォウ，フーシェン
ジャン，タオ
リャン，タオ
ラン，ジョン
ルー，チャン
Original Assignee
インシリコ メディシン アイピー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インシリコ メディシン アイピー リミテッド filed Critical インシリコ メディシン アイピー リミテッド
Publication of JP2025502602A publication Critical patent/JP2025502602A/ja
Publication of JP2025502602A5 publication Critical patent/JP2025502602A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024529739A 2021-12-22 2022-12-21 ピリミジン複素環式化合物、その調製方法及び医薬用途 Pending JP2025502602A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202111583828.0 2021-12-22
CN202111583828 2021-12-22
CN202210098381 2022-01-27
CN202210098381.6 2022-01-27
CN202210562007.7 2022-05-23
CN202210562007 2022-05-23
CN202211568373 2022-12-07
CN202211568373.X 2022-12-07
PCT/CN2022/140669 WO2023116761A1 (zh) 2021-12-22 2022-12-21 嘧啶杂环化合物，其制法与医药上的用途

Publications (2)

Publication Number Publication Date
JP2025502602A true JP2025502602A (ja) 2025-01-28
JP2025502602A5 JP2025502602A5 (enExample) 2025-12-18

Family

ID=86901286

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529739A Pending JP2025502602A (ja) 2021-12-22 2022-12-21 ピリミジン複素環式化合物、その調製方法及び医薬用途

Country Status (8)

Country Link
US (1) US20250145632A1 (enExample)
EP (1) EP4455132A4 (enExample)
JP (1) JP2025502602A (enExample)
KR (1) KR20240124992A (enExample)
CN (1) CN118647607A (enExample)
AR (1) AR128066A1 (enExample)
TW (1) TW202340211A (enExample)
WO (1) WO2023116761A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118556065A (zh) * 2022-01-28 2024-08-27 江苏奥赛康药业有限公司 含吲哚的大环类化合物及其应用
CN117964628A (zh) * 2022-10-24 2024-05-03 科辉智药生物科技(深圳)有限公司 作为cdk9抑制剂的大环类化合物及其应用
TW202500154A (zh) * 2023-06-19 2025-01-01 香港商英矽智能科技知識產權有限公司 大環類化合物、包含其的藥物組合物及其在醫藥上的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
MX358346B (es) * 2014-04-04 2018-08-15 Syros Pharmaceuticals Inc Inhibidores de la quinasa dependiente de ciclina 7 (cdk7).
SG11201900328WA (en) * 2016-07-13 2019-02-27 Jason Marineau Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA3088529A1 (en) * 2018-01-16 2019-07-25 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3873462A4 (en) 2018-11-01 2022-08-03 Syros Pharmaceuticals, Inc. CANCER TREATMENT METHODS IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLINE-DEPENDENT KINASE 7 (CDK7)
US20230115945A1 (en) * 2019-12-30 2023-04-13 Tyra Biosciences, Inc. Aminopyrimidine compounds
CN118556065A (zh) * 2022-01-28 2024-08-27 江苏奥赛康药业有限公司 含吲哚的大环类化合物及其应用

Also Published As

Publication number Publication date
CN118647607A (zh) 2024-09-13
EP4455132A1 (en) 2024-10-30
TW202340211A (zh) 2023-10-16
KR20240124992A (ko) 2024-08-19
EP4455132A4 (en) 2025-06-25
US20250145632A1 (en) 2025-05-08
AR128066A1 (es) 2024-03-20
WO2023116761A1 (zh) 2023-06-29

Similar Documents

Publication Publication Date Title
TWI841200B (zh) 雜環類化合物、藥物組成物及其應用
KR102894761B1 (ko) 치환된 헤테로환형 융합된 환형 화합물, 이의 제조 방법 및 이의 약학적 용도
CN113767106B (zh) 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途
EP4310091A1 (en) Pyrimidine-fused cyclic compound, preparation method therefor and use thereof
JP2025532218A (ja) ピリミジン縮合環化合物、ならびにその調製方法及び使用
US20260015350A1 (en) Azaquinazoline pan-kras inhibitors
CN106458912B (zh) 双环稠合的杂芳基或芳基化合物以及它们作为irak4拟制剂的用途
EP4159739A1 (en) Fused tricyclic compound, pharmaceutical composition thereof, and use thereof
BR112014014325A2 (pt) derivado de pirrol do tipo anel heteroarílico de seis membros, método de preparação do mesmo, e usos médicos do mesmo
KR20240124992A (ko) 피리미딘 헤테로시클릭 화합물, 그의 제조 방법 및 의약에서의 그의 용도
JP7840334B2 (ja) 芳香族複素環式化合物、薬学的組成物、及びその使用
KR20220018483A (ko) 비스헤테로사이클릭 카보닐 치환된 디하이드로피라졸 화합물, 이의 제조방법 및 이의 약학적 용도
US20240034731A1 (en) Aza-quinazoline compounds and methods of use
WO2025209278A1 (en) A pyrrolo [2, 3-b] pyridine derivative, and preparation method therefor and use thereof
CN116082337B (zh) 炔基取代的杂环化合物，其制法与医药上的用途
JP7833477B2 (ja) 血管拡張性失調症変異（ａｔｍ）キナーゼの選択的モジュレーターおよびその使用
RU2815814C1 (ru) Замещенное гетероциклическое конденсированное циклическое соединение, способ его получения и его фармацевтическое применение
US20250235456A1 (en) Methods of use for aza-quinazoline compounds
US20260137706A1 (en) Methods of treating inflammatory diseases
TW202547467A (zh) 雜芳基衍生化合物及其用途
KR20240016977A (ko) 2,8-디아자스피로[4.5]데칸 화합물
HK1234395B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251210